Cure: New Cure Center

August 11, 2015 By Benjamin Ryan

GSK (GlaxoSmithKline) has teamed up with the University of North Carolina at Chapel Hill to pursue HIV cure strategies. The HIV Cure center will have a home at the university and will partner with a new venture called Qura Therapeutics, owned jointly by GSK and the university. Qura will handle intellectual property, commercialization, manufacturing and governance of the center's pursuits. GSK has pledged $20 million toward the partnership over its first five years. A small team of researchers from the company will move to Chapel Hill to work at the center, where one focus will be on the "shock and kill" approach to curing HIV. In this method, HIV is brought out of its latent state in certain infected cells while the immune system is primed to better fight the virus.

© 2026 Smart + Strong All Rights Reserved.
http://beta.docker.poz.com/article/GSK-cure-strategy-27620-7595